(CercleFinance.com) – AB Science announces today that it has received authorization from the ANSM to initiate a Phase III study evaluating masitinib in patients with primary progressive multiple sclerosis (PPMS) or secondary multiple sclerosis progressive non-active (nSPMS).
The study plans to recruit 800 patients and the main objective will be to assess the effect of masitinib on the time to confirmed progression of the disability.
‘We are very excited to launch this confirmatory phase III study with masitinib in progressive forms of multiple sclerosis,’ commented Professor Patrick Vermersch, MD, principal investigator of the study and professor of neurology. at
the University of Lille.